FDA Expands Dapagliflozin Label to Include Reducing Risk of

Announced just more than a year after AstraZeneca announced topline results, the FDA has approved a label expansion to include reducing cardiovascular death and HF hospitalizations for dapagliflozin based on results of the phase 3 DELIVER trial.

Related Keywords

United States , America , Campbellp Dapagliflozin , Stephen Greene , Drug Administration , European Society Of Cardiology , Duke University School Of Medicine , Astrazeneca , Heart Failure Society Of America , European Society , Ruud Dobber , Biopharmaceuticals Business Unit , Heart Failure Society , Get With The Guidelines Heart Failure , Duke University School ,